Nurix enrolls first patient in Phase 3 CLL trial of bexobrutideg

August 4, 2026 1:00 AM

Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found